On September 3, 2024 Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, reported the successful closing of a $90 million Series D financing round, which includes the conversion of a convertible note (Press release, Circle Pharma, SEP 3, 2024, View Source;utm_medium=rss&utm_campaign=circle-pharma-closes-90-million-series-d-financing-to-advance-innovative-oral-macrocycle-therapies [SID1234646287]). The financing was led by The Column Group with participation from new and existing investors, including Nextech Invest and Euclidean Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The proceeds from the financing will be used to fund the clinical development of CID-078, Circle Pharma’s first-and-only-in-class cyclin A/B RxL inhibitor, and to support the development of the company’s portfolio of discovery programs built with its MXMO macrocycle platform.

"We are grateful for the continued support of such a strong syndicate of investors as we advance our pioneering work in macrocycle therapeutics," said David Earp, JD, Ph.D., CEO of Circle Pharma. "This financing not only enables us to progress CID-078 through critical stages of clinical development but also allows us to further advance our pipeline of innovative therapies targeting cancer and other serious diseases."

With this latest round of funding, Circle Pharma is well positioned to advance its mission of creating effective treatments for cancer and other serious illnesses.